Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data
Nuvation Bio’s glioma drug has touted a 36-month progression-free survival (PFS) rate of 79% with nearly 40 months of follow-up, with its advancement to…
Oncology
-
-
Agenus’ metastatic colorectal cancer combo achieves 33% three-year OS rate
Agenus’s metastatic colorectal cancer (mCRC) combination therapy has continued to show benefit after three years of treatment, with a median…
-
Genmab and AbbVie’s Epkinly combo improves PFS in second-line DLBCL trial
Genmab’s Phase III trial of a combination therapy including its bispecific T-cell engager (BiTE) combination, including Epkinly, has met its…
-
Novocure’s Optune Gio fails to show benefit at earlier stage
Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit…
-
Verastem Oncology’s pancreatic cancer combo shows 86% OS rate
Verastem Oncology’s pancreatic cancer combination has shown an 86% overall survival (OS) rate in a Phase Ib/IIa trial. In the…
-
EHA26: BTK combos in CLL/SLL showing earlier line promise
At the European Hematology Association (EHA) 2026 Congress, several therapies for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
-
EHA26: AstraZeneca battles Roche in untreated follicular lymphoma
At the 2026 European Hematological Association (EHA) conference, held in Stockholm on 11–14 June, AstraZeneca shared preliminary safety data from…
-
ASCO26: GLP-1RAs linked with mortality reduction in patients with solid tumours
As glucagon-like peptide-1 receptor agonists (GLP-1RA) appear to be taking over the world, research using real-world data (RWD) is showing…
-
Lilly’s JAK2 inhibitor from $2.3bn acquisition shows early promise
Eli Lilly’s type II JAK2 inhibitor, which it acquired through the $2.3bn acquisition of Ajax Therapeutics earlier this year, has…
-
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at…
